IMMUNIC, INC. Quarterly Debt-to-equity in % from Q1 2020 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Immunic, Inc. quarterly Debt-to-equity history and growth rate from Q1 2020 to Q2 2024.
  • Immunic, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 39 %, a 135% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 39 +22.4 +135% Jun 30, 2024
Q1 2024 36.5 +24.1 +194% Mar 31, 2024
Q4 2023 34.1 +24 +239% Dec 31, 2023
Q3 2023 21.6 +12.3 +131% Sep 30, 2023
Q2 2023 16.6 +8.01 +93.7% Jun 30, 2023
Q1 2023 12.4 +2.9 +30.5% Mar 31, 2023
Q4 2022 10.1 -0.47 -4.47% Dec 31, 2022
Q3 2022 9.37 -0.04 -0.43% Sep 30, 2022
Q2 2022 8.55 -0.15 -1.73% Jun 30, 2022
Q1 2022 9.52 +1.41 +17.4% Mar 31, 2022
Q4 2021 10.5 +3.18 +43.3% Dec 31, 2021
Q3 2021 9.42 +0.39 +4.32% Sep 30, 2021
Q2 2021 8.7 -3.37 -27.9% Jun 30, 2021
Q1 2021 8.1 -2.21 -21.4% Mar 31, 2021
Q4 2020 7.34 Dec 31, 2020
Q3 2020 9.03 Sep 30, 2020
Q2 2020 12.1 Jun 30, 2020
Q1 2020 10.3 Mar 31, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.